Click here to read the full article

Pfiz­er Inc. said a final analy­sis of clin­i­cal-tri­al data showed its Covid-19 vac­cine was 95% effec­tive, paving the way for the com­pa­ny to apply for the first U.S. reg­u­la­to­ry autho­riza­tion for a coro­n­avirus shot with­in days.

The U.S. drug­mak­er and part­ner BioN­Tech SE said their vac­cine pro­tect­ed peo­ple of all ages and eth­nic­i­ties, with no sig­nif­i­cant safe­ty prob­lems so far in a tri­al that includes almost 44,000 participants.

Pfiz­er shares rose 2.7% in pre­mar­ket trad­ing, with BioN­Tech Amer­i­can deposi­tary receipts up 7.3%. Euro­pean stocks extend­ed their gains after the news, with the Stoxx Europe 600 up 0.4%